Cite

    Patel, S. et al. (2019). Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 125 (15), pp. 2610-2620. [Online].